Physician profile
Josephine E Drew
NPI 1881636629
$7,390.83
in general payments reported to CMS, 2019-2025
49 companies · $1,984 in 2025
The $1,984 reported for 2025 was more than what 95% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $716 · 2020: $975 · 2021: $1,139 · 2022: $810 · 2023: $600 · 2024: $1,167 · 2025: $1,984.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,750.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,750.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,234.31 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Amgen INC. | $1,015.41 | 2019-2025 | Repatha, Otezla, Evenity |
| Abbvie INC. | $790.45 | 2021-2025 | Ubrelvy, Qulipta, Vraylar |
| Pfizer INC. | $710.52 | 2019-2025 | |
| Glaxosmithkline, LLC. | $306.39 | 2019-2025 | Trelegy Ellipta, Arexvy, Nucala |
| Boehringer Ingelheim Pharmaceuticals, INC. | $300.42 | 2019-2022 | |
| Novo Nordisk INC | $290.40 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Lilly USA, LLC | $221.68 | 2019-2025 | Jardiance, Zepbound, Mounjaro |
| Astellas Pharma US INC | $212.04 | 2019-2025 | Veozah |
| Madrigal Pharmaceuticals | $193.24 | 2025 | Rezdiffra |
| Daiichi Sankyo INC. | $187.96 | 2019-2024 | Injectafer |
| Novartis Pharmaceuticals Corporation | $184.01 | 2019-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $149.18 | 2020-2025 | Xifaxan |
| Amarin Pharma, INC. | $144.14 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $135.21 | 2020-2025 |
Show all 49 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Josephine Drew listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.